Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries
This article was originally published in The Pink Sheet Daily
Executive Summary
With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.
You may also be interested in...
Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter
FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.
Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point
Bristol-Myers Squibb’s “anti-PD-1,” an antibody that gets between immune system T-cells out to destroy cancer cells and a cancer defense mechanism that would tie them up, caught the fancy of attendees at the American Society of Clinical Oncology annual meeting in Chicago with Phase I data indicating the drug could be safer and more effective than Bristol’s breakthrough immunotherapeutic for melanoma, Yervoy.
Plavix Takes A Final Bow, But Will It Go Gracefully?
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.